Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
Healthcare
$19.84 +3.06%
+$0.39 today
- Market cap
- $682.28M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
52W Low $5.55High $13.51
Volume 0.16M
Average 0.08M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$16.01M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$29.11M
FY 2025 · Annual
+149.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.89M | 1.71M | 4.71M | 4.86M | 1.35M |
| Change in Working Capital | 1.49M | 3.82M | 1.74M | 1.9M | 4.4M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 1.85M | (139K) | (273K) | 3.78M |
| Other Working Capital | 1.49M | 1.97M | 1.88M | 2.17M | 625K |
| Other Non-Cash Items | 0 | 0 | (139K) | 0 | 4.68M |
| Operating Cash Flow | (9.5M) | (13.56M) | (15.95M) | (12.25M) | (16.01M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 15.25M | 31.88M | 5.29M | 12.04M | 29.11M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (4.07M) | 9.8M | (382K) | 0 |
| Financing Cash Flow | 15.25M | 27.81M | 15.09M | 11.65M | 29.11M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 5.74M | 14.25M | (867K) | (593K) | 13.1M |
| Free Cash Flow | (9.5M) | (13.56M) | (15.95M) | (12.25M) | (16.01M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$26.4M
+ D&A$0
+ Stock-Based Comp$1.4M
+ Deferred Tax$0
+ Working Capital$4.4M
+ Other Non-Cash$4.7M
= Operating Cash Flow-$16.0M
- Capex$0
= Free Cash Flow-$16.0M
Analysis
FY2025 free cash flow is -$16.0M. FCF conversion is 60.5% of net income. Operating cash flow was -$16.0M, with capex of $0. The largest bridge item is Other Non-Cash at $4.7M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| EFFECT | EFFECT filing | Aug 28, 2026 | |
| S-3 | S-3 filing | Aug 21, 2026 | |
| 8-K | Current report | Aug 21, 2026 |
Does NVCT generate free cash flow?
Nuvectis Pharma, Inc. (NVCT) generated -$16.01M of free cash flow in fiscal 2025.
How much operating cash flow does NVCT produce?
Operating cash flow was -$16.01M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.